Chelsie Derman is an associate editor for HCPLive who covers allergy and psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.
She can be reached at [email protected].
Mindfulness-Oriented Recovery Enhancement plus methadone treatment is a promising treatment option for patients with opioid use disorder, having been significantly associated with less return to drug use and methadone treatment dropout, a new study found.
A new study found patients who scored high on the Insomnia Severity Index questionnaire had a longer hospital stay length, increased risk of 30-day readmission, and increased risk of 30-day emergency department or urgent care visits.
Young adults aged 18 – 19 are the age range who discontinues ADHD medication the most, according to a new study.
A nationwide Taiwan-based study found benzodiazepine use during pregnancy was linked to roughly a 70% increased risk of miscarriage.
Infants and toddlers during the COVID-19 pandemic are associated with a higher odd of positive ASQ:SE-2 screenings. The findings suggest the pandemic caused delays in children’s socio-emotional development.
After participants with autism wore biosensors tracking physiological signals, a logistic regression predicted aggressive behaviors 3 minutes before it happened.
In a new study, children had 8 - 40% higher odds of a psychiatric condition if their parents scored 1 SD above the mean on the general psychopathology. This demonstrates how parents with psychiatric disorders have a higher likelihood of passing it down to their children.
Miller discusses the EMERGENT-2 trial and the benefits of xanomeline-trospium for treating adults with schizophrenia, for which the treatment is currently awaiting FDA decision.
Jennifer Mitchell, PhD, discusses MAPS Public Benefit Corporations’ recent New Drug Application submission for MDMA-Assisted Therapy for PTSD and what the treatment’s potential approval could mean for people with PTSD.
The FDA approved zuranolone for postpartum depression in August, and the drug recently hit the market for patients this month. Experts are celebrating its delivery of care and rapid response rate.
Maternal height is linked to specific adverse pregnancy events in women with gestational diabetes mellitus, according to a new study. The investigators found shorter women had higher rates of low birth rate and primary c-sections, but taller women had higher rates of abnormal neonatal ponderal index, postpartum hemorrhage, and macrosomia.
Tight glycemic target treatment compares similarly to less-tight glycemic target treatment in terms of how it affects the mental health status of women with gestational diabetes mellitus.
In a phase 3 EMERGENT-2 trial, the study found 55% of participants with schizophrenia taking xanomeline-trospium had a ≥30% improvement from baseline to week 5, compared to the placebo group.
A phase 2b clinical trial met its primary endpoint with positive topline results, showing MM-120 (lysergide d-tartrate) can reduce symptoms of generalized anxiety disorder, reflected in the Hamilton Anxiety rating scale scores.
A new study demonstrated hemoglobin levels significantly increased with ziltivekimab, showing the monoclonal antibody has the potential to serve as a new treatment method for anemia.
According to a new study, laparoscopic donor nephrectomy performed better than open donor nephrectomy regarding hospital stay length, urinary catheterization, operating time, and blood loss.
Presented at ASH 2023, a new study demonstrated physical activity does not increase bleeding for patients with hemophilia A as patients with low physical activity still experienced frequent bleeding.
Late shift work is associated with sleep disorders the most for females, the age group <30 years old, people who live alone or with roommates, have only up to an elementary or secondary education, and people who work the night shift.
Guizhi-Shaoyao-Zhimu Decoction treatment helps lower levels of blood uric acid, c-reactive proteins, erythrocyte sedimentation rate, interleukin 6, interleukin 8, tumor necrosis factor, and visual analogue scale more than conventional treatment for gout.
Presented at ASH 2023, findings of a new study showed patients with sickle cell disease and venous thromboembolism have longitudinal worsening of left ventricular diastolic and right-sided cardiac function.
In a new study, a subgroup analysis demonstrated a reduced risk of colorectal cancer among patients <65 years old with gout.
Presented at ASH 2023, opioid use disorder in sickle cell disease patients with vaso-occlusive is associated with a longer hospital stay and greater cost.
Findings of a new study suggest COVID-19 does not serve as risk factor for the development of VTE in pediatric cancer patients.
In a new study, patients with ADHD on cannabis-based medicinal products had significant improvements for anxiety, sleep quality, and health-related quality of life.
In a new study, inserting the XEN-45 implant in patients with uncontrolled uveititc glaucoma prevented conventional glaucoma surgery in 83.3% of patients.
Gene therapy with mRNA is more cost-efficient, has a better safety profile, and is more reproducible than the viral vector, AAV, currently used for gene therapy to improve inherited retinal diseases.
A new sleep survey found 91% of respondents lost sleep due to binge-watching TV, and only 8% of Americans reported never staying up past their bedtime for this reason.
In a new pooled analysis of 3 pharmacokinetic studies, the investigators confirmed the bioequivalence, safety, and immunogenicity between biosimilar MB02 and European Union approved bevacizumab and US-approved bevacizumab.
Aotearoa, New Zealand had a mandatory adalimumab biosimilar transition from March – September 2022. A survey reveals low satisfaction with biosimilar’s quality, as well as the lack of alcoholic wipes and a support program.
In a new study focusing on adults with type 1 diabetes and mild-moderate depressive symptomatology, a CBT program helped depression symptoms, quality of life, anxiety, treatment adherence, and total diabetes-related stress in emotional, physical, and impersonal subscales.
